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Autoimmune retinopathy associated
with systemic lupus erythematosus:
A diagnostic dilemma
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David Salz1, Erik Kruger6, Alex V. Levin1,7
Abstract:
Visual loss in systemic lupus erythematosus (SLE) due to autoimmune retinopathy (AIR) is rare and
easily misdiagnosed as hydroxychloroquine retinopathy. We report the rare clinical presentation
of severe visual loss in a patient with SLE due to nonparaneoplastic AIR as differentiated from
hydroxychloroquine toxicity. A 70‑year‑old female diagnosed and treated for lupus for 17 years
and had been taking hydroxychloroquine for 15 years. Over the past 2 years, she developed
progressive peripheral visual loss oculus uterque which rapidly advanced in the latter 6 months.
Hydroxychloroquine toxicity was initially suspected, but diagnostic testing revealed a retinal
degeneration. Antiretinal autoantibody testing using Western blot analysis revealed autoantibodies
against 44‑kDa, 46‑kDa (anti‑enolase), and 68‑kDa proteins. Visual acuity improved in the first
6 months of treatment with mycophenolate mofetil. Our case suggests that AIR should be considered
in the differential diagnosis of rapid, severe visual loss in patients with hydroxychloroquine treatment.
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Introduction

A

utoimmune retinopathies (AIRs) are
a group of autoantibody‑mediated
retinal degenerations. Three subtypes
have been identified: cancer‑associated
retinopathy (CAR), melanoma‑associated
retinopathy (MAR), and nonparaneoplastic
AIR (npAIR). [1,2] AIR is characterized
by acute or subacute progressive visual
deterioration, visual field loss, abnormal
electroretinography (ERG), the presence
of circulating antiretinal autoantibodies
(ARAs), and often a normal appearing
retina.[2]
Systemic lupus erythematosus (SLE) is a
chronic autoimmune disorder, characterized
by the production of autoantibodies against
cell surfaces and abnormal deposition of
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circulating immune complexes in various
tissues, both of which result in end‑organ
damage.[3] The ocular manifestations are
highly variable and can lead to severe visual
loss. Previously reported posterior segment
manifestations include retinal vasculitis or
vascular occlusion, choroidopathy, optic
neuritis, and toxic retinopathy related to
the use of hydroxychloroquine in SLE
treatment.[1,3] Reports of SLE‑associated AIR
are rare and may be incorrectly ascribed to
hydroxychloroquine toxicity.[1]

Case Report
A 70‑year‑old Caucasian female, with no
family history of retinal degeneration,
was first diagnosed with SLE in 1995 in
another center. Her prior manifestations
of the disease included synovitis,
pleuropericarditis, hemolytic anemia,
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immune thrombocytopenia, positive antinuclear
antibody (ANA), positive double‑stranded DNA (dsDNA)
antibody, positive anti‑SSA antibody, positive anti‑SSB
antibody, and hypocomplementemia. She experienced
decreasing vision, nyctalopia, and constricted peripheral
vision beginning in 2010 and hydroxychloroquine was
stopped. Her SLE had been stable on hydroxychloroquine
400 mg daily for 15 years (total dose 2190 g) and low‑dose
prednisone for 17 years. She was 59 inches (149.9 cm)
in height and weighed 53.5 kg (ideal body weight
44.6 kg). [4] Over the past 2 years, zoledronic acid,
metoprolol, hydrochlorothiazide, allopurinol, and
potassium supplements were used for the treatment of
her osteoporosis, hypertension, and gout, respectively.
Although her SLE was stable and well controlled, with
negative anti‑dsDNA and 1:640 ANA, over the past
2 years, she had a progressive decline of her peripheral
vision making it difficult for her to use her vision.
Hydroxychloroquine was stopped. Her vision rapidly
declined in the first 6 months and then slowly thereafter.
Cataract surgery performed after the first 6 months did
not result in visual improvement.
At her first visit with us in 2012, best‑corrected visual
acuity in her current spectacles (plano +0.75 axis 55 right
eye, +0.50 +0.5 axis 94 left eye) was 20/40 in each eye with
difficulty finding the letters on the Snellen chart in each
eye. She was unable to identify any Ishihara color plates
in either eye other than the control plates. Pupils were
reactive and equal, without relative afferent pupillary
defect or paradoxical pupils. Ocular motility was full, and
there was no strabismus. Anterior segment examination
was normal with posterior chamber intraocular lenses in
both eyes. Dilated retinal examination was remarkable
in both eyes for optic nerve pallor, retinal arterial
attenuation, blunted foveal reflex, and mid‑peripheral
pigmentary mottling [Figure 1].

Goldmann visual field showed constriction to <10° in
each eye without peripheral islands. Full‑field ERG
and multifocal ERG (ffERG and mfERG) performed in
accordance with the International Society for Clinical
Electrophysiology of vision protocol were isoelectric to
all stimuli. Intravenous fluorescein angiography showed
attenuation of the retinal vessels with some transmission
defects in the retinal pigment epithelium. Optical
coherence tomography (OCT) showed the absence
of the macular photoreceptors, loss of normal retinal
lamination, and gliosis on the retinal surface of both
eyes [Figure 2]. Fundus autofluorescence (FAF) showed
diffuse punctate hyperautofluorescence throughout the
posterior pole with the suggestion of more intense flecks
concentrated in the macula around the fovea [Figure 3].
Peripheral FAF images were not obtained.
Western blot analysis to detect antiretinal
autoantibodies (Ocular Immunology Laboratory, Casey
Eye Institute, Oregon, USA) revealed autoantibodies
against 44‑kDa, 46‑kDa (anti‑enolase), and 68‑kDa
proteins. CT scan of the brain, whole body magnetic
resonance imaging, and mammography were all normal.
There were no skin lesions suggestive of melanoma. No
genetic testing for retinal dystrophy was performed.
Mycophenolate mofetil 500 mg twice a day was started
in January 2013. Her vision improved to 20/30–40
both eyes 2.5 months thereafter and 20/25–30 oculus
uterque at 6 months. At last follow‑up in June 2014, her
best‑corrected visual acuity was 20/40 OD but decreased
to 20/100 OS. She had sustained fractures from a fall in
her left tibia and right wrist in 2014 requiring surgery.
Hence, the treatment for her AIR was interrupted. She
was unable to perform visual field testing. There was new
foveal hyperautofluorescence in the left eye more than the
right that had worsened since her presentation [Figure 3].

a
a

b
Figure 1: Fundus photographs: Right eye (a); left eye (b). Note bilateral optic
nerve pallor, retinal arterial attenuation, blunted foveal reflex, and mid‑peripheral
pigmentary mottling
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b
Figure 2: Optical coherence tomography in 2012: Right eye (a); left eye (b). Optical
coherence tomography showed the absence of the macular photoreceptors, loss of
normal retinal lamination, and gliosis on the retinal surface of both eyes
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Figure 3: Fundus autofluorescence in October 4, 2013 (a and b) diffuse
punctate hyperautofluorescence throughout the posterior pole without the more
characteristic easily discernible perifoveal ring of hydroxychloroquine toxicity.
October 6, 2014 (c and d) There is new foveal hyperautofluorescence in the left eye
more than the right

OCT was unchanged. ffERG and mfERG showed no
recovery of response and remain isoelectric.

Discussion
AIR is a retinopathy resulting from an immunological
attack on the retina by ARAs directed against retinal
antigens such as rod, cone, and Muller cells.[1,2] AIR is
characterized by cone and rod dysfunction associated
with photoaversion, subacute progressive loss of vision,
nyctalopia, abnormalities of color perception, central
or paracentral scotoma, and decreased photopic and
scotopic responses on ERG.[2] npAIR shares the same
features as CAR/MAR but occurs in the absence of
malignant tumor.[5‑8] The clinical spectrum of AIR is
heterogeneous and diverse. The fundus can appear
normal or show signs of retinal degeneration including
attenuated retinal vessels, disc pallor, and RPE mottling
or atrophy.[9]
Numerous antiretinal antibodies have been described in
AIR. Among them, antibodies against recoverin (23‑kDa)
and enolase (46‑kDa) are the most common.[2,6] Both
anti‑recoverin and anti‑enolase antibodies can be found
in patients with CAR and npAIR.[2] It had been suggested
that the anti‑recoverin antibody is more specific to
paraneoplastic retinopathy and the anti‑enolase antibody
is more sensitive[6] although a significant portion of
normal people have been reported to carry anti‑recoverin
antibody.[10] Hence, the interpretation of these antiretinal
antibodies should be cautious.[11]
There are several causes of visual dysfunction in
SLE. Pigmentary retinopathy is uncommon.
Hydroxychloroquine retinopathy must be considered.
174

A cumulative dose of more than 1000 g has been
considered as a risk factor.[12] Our patient had been treated
with a potentially toxic cumulative dose of 2190 g,[12] but
her fundus, diagnostic testing and clinical features are
not consistent with hydroxychloroquine retinopathy.
She did not demonstrate many of the common signs
of hydroxychloroquine retinopathy: “bull’s eye”
maculopathy, spared central vision, paracentral
visual field defect, FAF findings of perimacular
hyperautofluorescent and hypoautofluorescent rings
with or without hyperautofluorescent specks surrounding
the fovea, typical OCT findings, and normal ffERG.[12‑14]
One report of retinal toxicity from hydroxychloroquine
with a similar cumulative dose to our patient did not
show similar clinical features.[13] The patient first saw us
in 2012 with a history of progressive visual loss within
2 years even though the hydroxychloroquine had been
stopped. She did not have bull’s eye maculopathy.
She demonstrated severely constricted visual fields
without peripheral islands, diffuse retinal structure
disruption on OCT without “flying saucer” sign,
diffuse hyper‑ and hypoautofluorescence on FAF, and
isoelectric ffERG and mfERG, all of which are not typical
of hydroxychloroquine retinopathy.[13,15‑17] Although
late deterioration can rarely occur despite stopping
hydroxychloroquine, our patient’s features do not
unequivocally suggest this possibility.[13] Yet, there is
no way to prove she did not have very severe end‑stage
hydroxychloroquine retinopathy.
We also considered the possibility of coincidental
late‑onset primary retinitis pigmentosa. In later
onset retinal degeneration (LORD), retinal findings
including yellow subretinal deposits, chorioretinal
atrophy, and choroidal neovascularization, all are very
different from those seen in our patient.[18] Diffuse
hyperautofluorescence has been reported in patients
with PRPH 2 mutation;[19] our patient’s rapid progression
of visual dysfunction would be atypical for a mutation
in this gene as well as LORD or autosomal dominant
retinitis pigmentosa. Therefore, molecular genetic testing
was not pursued. The presence of ARAs is supportive
evidence for a diagnosis of AIR.[2] Anti‑enolase antibody
is reported to be associated with central visual loss,
and in some cases, both cone and rod functions were
similarly affected as in our patient.[20] Without evidence
of neoplasia, we believe our patient has npAIR. Periodic
screening for malignancy will still be conducted every
year. Late onset of detectable malignancy has previously
been reported.[5]
Our patient had painless subacute visual field loss,
pigmentary retinopathy, isoelectric ERG responses,
and OCT findings, which show loss of the outer retinal
segment and thinning of the retina, consistent with
previous reports of AIR.[21,22] The OCT of both eyes
Taiwan J Ophthalmol - Volume 7, Issue 3, July-September 2017
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is severe. The image quality of our patient’s OCT is
only fair and we believe only some healthy‑surviving
photoreceptors would be able to give patient‑compatible
visions, which OCT may fail to show. FAF in our patient
initially showed diffuse intense hyperautofluorescent
flecks throughout the posterior pole without the
more characteristic easily discernible perifoveal
ring of hydroxychloroquine toxicity. Follow‑up FAF
showed new foveal hyperautofluorescence and RPE
mottling. To our knowledge, there are only three prior
reports regarding FAF in AIR which both of which
showed a hyperautofluorescent ring in the parafoveal
region.[21,23,24] Although this pattern is similar to that
seen in retinitis pigmentosa, the authors suggest that
the hyperautofluorescent ring is less intense than seen
in patients with retinitis pigmentosa because of the
shorter duration in course of their patients’ disease.[23]
Our patient’s FAF findings are different from the prior
studies perhaps because our patient had more severe
retinal damage compared to those patients. Areas
of fundus hyperautofluorescence were reported to
correspond to the destruction of the outer retinal
structure.[21] In addition, we recently found an interesting
report by Polascik et al.[24] They reported a case of
AIR in a patient not taking hydroxychloroquine who
shares many common features with our patient (good
central vision, attenuated retinal vessels, parafoveal
hyperautofluorescence, and loss of outer retinal layers).
This also supports AIR although we acknowledge
this could share similar features with very late‑staged
hydroxychloroquine retinopathy. The visual field test
in our patient is much more severe than patients in
the prior studies. Advanced field loss in this patient
may be secondary to delayed detection of AIR by a
misattribution of her symptoms to hydroxychloroquine.
The high cumulative dose of hydroxychloroquine might
also compound the damage to the retinal photoreceptors.
Perhaps the most convincing factor that supports an
autoimmune role for her visual loss is the worsening
of her vision when her mycophenolate mofetil was
discontinued because of fractures and associated surgery.

considered in the differential diagnosis of rapid, severe
visual loss in patients rather than the complications of
hydroxychloroquine treatment. In the future, perhaps
immunohistochemistry studies may be helpful to
elucidate the roles of retinal antibodies in similar patients
and help differentiate AIR from hydroxychloroquine
toxicity.

Hydrochlorothiazide, her antihypertensive
medication, has been reported to be associated with
retinopathy. [25] The reported symptoms are central
scotoma and metamorphopsia. The fundus photograph
in that report shows a subfoveal yellowish‑gray lesion
in the acute phase and a flat partially pigmented retinal
pigment epithelial scar 6 months later. Our patients did
not share any characteristics with hydrochlorothiazide
retinopathy.

11.

There are many causes of severe visual loss in SLE
including lupus retinopathy, vascular complications, and
hydroxychloroquine toxicity. npAIR is a rare cause of
visual loss in SLE. Our case suggests that AIR should be

15.
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